Kempen & Co acted as Co-Lead Manager in Zealand Pharma’s DKK 786m Capital Increase
Zealand Pharma (Nasdaq: ZEAL) is a biotechnology company focused on discovering, developing, and commercialising peptide-based medicines. More than ten drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market, and three candidates are in late-stage development.
In March 2022, Zealand Pharma announced a new strategy to pursue strategic partners for the commercialisation and co-development of late-stage clinical assets and prioritize resources on R&D.
The company has development partnerships with a number of blue-chip pharma companies as well as commercial partnerships for its marketed products.
Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma has a team in the U.S.
In the last twelve months, Kempen & Co has successfully completed a large number of equity capital markets transactions in its Life Sciences & Healthcare franchise. Recent transactions include: